Skip to content

Search

The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial

Structural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after newborn screening. We hypothesised that azithromycin, given three times weekly to infants with cyst…

Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand

This position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a mult…

Pseudomonas aeruginosa modulates neutrophil granule exocytosis in an in vitro model of airway infection

A population of neutrophils recruited into cystic fibrosis (CF) airways is associated with proteolytic lung damage, exhibiting high expression of primary granule exocytosis marker CD63 and reduced phagocytic receptor CD16. Causative factors for this…

Wal-yan researchers welcomed at scientific meeting in New Zealand

More than 14 researchers from the Wal-yan Respiratory Research Centre will be welcomed as presenters and facilitators at The Thoracic Society of Australia and New Zealand and The Australia and New Zealand Society of Respiratory Science (TSANZSRS) An…

New trial aims to nip chronic lung disease in the bud for First Nations kids

WA researchers will use a $1.97 million Medical Research Future Fund grant to develop a strategy for better follow-up of First Nations children after they’ve been hospitalised for respiratory infections, in a bid to halt the slide into more severe l…